SCHEMBL3474515

SCHEMBL3474515

CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(=O)NCCc4ccccn4)nn3-c3ccccc3Cl)s2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.67
NR1H2 P55055 6/20 0.67
NR1H3 Q13133 6/20 0.67
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
SLC12A2 P55011 1/20 0.39
SLC12A5 Q9H2X9 1/20 0.39
SLC16A3 O15427 2/20 0.38
SLC16A1 P53985 2/20 0.38
MCTS1 Q9ULC4 1/20 0.38
STAT6 P42226 1/20 0.38
HTT P42858 2/20 0.38
ATM Q13315 1/20 0.38
MALT1 Q9UDY8 1/20 0.38
TSHR P16473 1/20 0.38
GAA P10253 1/20 0.37
CNR1 P21554 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15641686 0.93 RXRA (0.70) RXRANR1H2NR1H3ALDH1A1L3MBTL1
SCHEMBL3471799 0.90 RXRA (0.65) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL14624827 0.89 RXRA (0.75) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3474122 0.88 RXRA (0.73) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3472973 0.87 NR1H2 (0.77) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3472828 0.87 RXRA (0.67) RXRANR1H2NR1H3LMNAMALT1
SCHEMBL3477287 0.87 RXRA (0.67) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3474729 0.86 RXRA (0.71) RXRANR1H2NR1H3MALT1CNR1
SCHEMBL3474852 0.86 RXRA (0.71) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3473025 0.86 RXRA (0.73) RXRANR1H2NR1H3L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.